Xencor (XNCR) Current Deferred Revenue (2013 - 2024)
Xencor's (XNCR) quarterly Current Deferred Revenue came in at $36.5 million in Q2 2024, up 361.67% year-on-year from $7.9 million in Q3 2023, and up 6.99% on a QoQ basis from $34.1 million in Q1 2024.
Xencor (XNCR) Current Deferred Revenue (2013 - 2024) Analysis & Trends
Xencor (XNCR) has 12 years of Current Deferred Revenue data on file, last reported at $36.5 million in Q2 2024.
- On a quarterly basis, Current Deferred Revenue rose 361.67% year-over-year to $36.5 million in Q2 2024; TTM through Jun 2024 was $36.5 million, a 361.67% increase from a year earlier, with the FY2022 full-year figure at $30.3 million, down 18.71% from the prior year.
- Current Deferred Revenue for Q2 2024 stood at $36.5 million, up from $34.1 million in the prior quarter.
- Over the last five years, Current Deferred Revenue for XNCR reached as high as $92.6 million in Q4 2020 and fell as low as $7.9 million in Q2 2023.
- Historically, Current Deferred Revenue has averaged $37.0 million across 5 years, with a median of $35.3 million in 2022.
- Across the five-year window, Current Deferred Revenue tumbled 77.62% in 2023 and soared 361.67% in 2024, its largest moves.
- Year by year, Current Deferred Revenue stood at $92.6 million in 2020, then slumped by 59.72% to $37.3 million in 2021, then retreated by 18.71% to $30.3 million in 2022, then tumbled by 69.58% to $9.2 million in 2023, then jumped by 295.49% to $36.5 million in 2024.
- Per Business Quant data, the three most recent Current Deferred Revenue figures were $36.5 million in Q2 2024, $34.1 million in Q1 2024, and $9.2 million in Q3 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Xencor | 1.47 Bn | 1.09 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 36.47 Mn |
| Mar 31, 2024 | 34.09 Mn |
| Sep 30, 2023 | 9.22 Mn |
| Jun 30, 2023 | 7.90 Mn |
| Mar 31, 2023 | 30.10 Mn |
| Dec 31, 2022 | 30.32 Mn |
| Sep 30, 2022 | 35.20 Mn |
| Jun 30, 2022 | 35.30 Mn |
| Mar 31, 2022 | 35.50 Mn |
| Dec 31, 2021 | 37.30 Mn |
| Sep 30, 2021 | 13.00 Mn |
| Jun 30, 2021 | 19.20 Mn |
| Mar 31, 2021 | 77.80 Mn |
| Dec 31, 2020 | 92.60 Mn |
| Sep 30, 2020 | 43.80 Mn |
| Jun 30, 2020 | 44.70 Mn |
| Mar 31, 2020 | 46.20 Mn |
| Dec 31, 2019 | 45.21 Mn |
| Sep 30, 2019 | 48.20 Mn |
| Jun 30, 2019 | 45.50 Mn |